UBX-306 / Ubix Therap, NeoImmuneTech - LARVOL DELTA

Discovery of UBX-306 as a potent, selective, and orally bioavailable HPK1 degrader (AACR 2025) - "We demonstrate that potent HPK1 degraders, effectively activate immune cells and inhibit tumor growth in mouse syngeneic tumor models as single agents. These degraders enhance IL-2 and IFNγ production while overcoming immunosuppressive factors. Further, in vivo studies will deepen our understanding of HPK1 degradation as a promising immunomodulatory strategy for enhancing anti-tumor immunity."

Colorectal Cancer • Oncology • Solid Tumor • IFNG • LCP2